U.S. pharma big copyright scrapped two experimental weight loss capsules past calendar year—a when-day-to-day capsule, lotiglipron, because of elevated liver enzymes as well as a two times-everyday tablet, danuglipron, because of robust Unwanted side effects—but CEO Albert Bourla has